Target Information

Target General Information

Target ID

T29083 (Former ID: TTDI03196)

Target Name

Proto-oncogene c-Fes (FES)

Synonyms

p93c-fes; Tyrosine-protein kinase Fes/Fps; Proto-oncogene c-Fps; Feline sarcoma/Fujinami avian sarcoma oncogene homolog; FPS

Click to Show/Hide

Gene Name

FES

Target Type

Literature-reported target

[1]

Function

Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT. Plays a role in the regulation of mast cell degranulation. Plays a role in the regulation of cell differentiation and promotes neurite outgrowth in response to NGF signaling. Plays a role in cell scattering and cell migration in response to HGF-induced activation of EZR. Phosphorylates BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1, PECAM1, STAT3 and TRIM28. Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading.

Click to Show/Hide

BioChemical Class

Kinase

UniProt ID

FES_HUMAN

EC Number

EC 2.7.10.2

Sequence

MGFSSELCSPQGHGVLQQMQEAELRLLEGMRKWMAQRVKSDREYAGLLHHMSLQDSGGQS
RAISPDSPISQSWAEITSQTEGLSRLLRQHAEDLNSGPLSKLSLLIRERQQLRKTYSEQW
QQLQQELTKTHSQDIEKLKSQYRALARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLF
AHHNRYVLGVRAAQLHHQHHHQLLLPGLLRSLQDLHEEMACILKEILQEYLEISSLVQDE
VVAIHREMAAAAARIQPEAEYQGFLRQYGSAPDVPPCVTFDESLLEEGEPLEPGELQLNE
LTVESVQHTLTSVTDELAVATEMVFRRQEMVTQLQQELRNEEENTHPRERVQLLGKRQVL
QEALQGLQVALCSQAKLQAQQELLQTKLEHLGPGEPPPVLLLQDDRHSTSSSEQEREGGR
TPTLEILKSHISGIFRPKFSLPPPLQLIPEVQKPLHEQLWYHGAIPRAEVAELLVHSGDF
LVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDHLLSTQQPLTKK
SGVVLHRAVPKDKWVLNHEDLVLGEQIGRGNFGEVFSGRLRADNTLVAVKSCRETLPPDL
KAKFLQEARILKQYSHPNIVRLIGVCTQKQPIYIVMELVQGGDFLTFLRTEGARLRVKTL
LQMVGDAAAGMEYLESKCCIHRDLAARNCLVTEKNVLKISDFGMSREEADGVYAASGGLR
QVPVKWTAPEALNYGRYSSESDVWSFGILLWETFSLGASPYPNLSNQQTREFVEKGGRLP
CPELCPDAVFRLMEQCWAYEPGQRPSFSTIYQELQSIRKRHR

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Drug Binding Sites of Target

Top

Ligand Name: Staurosporine

Ligand Info

Structure Description

Crystal structure of human feline sarcoma viral oncogene homologue (v-FES) in complex with staurosporine and a consensus peptide

PDB:3CBL

Method

X-ray diffraction

Resolution

1.75 Å

Mutation

[3]

PDB Sequence

SMIPEVQKPL

⁴⁵⁵

HEQLWYHGAI

⁴⁶⁵

PRAEVAELLV

⁴⁷⁵

HSGDFLVRES

⁴⁸⁵

QQEYVLSVPR

⁵⁰²

HFIINLYRLF

⁵²⁰

PSIPLLIDHL

⁵³⁰

LSTQQPLVVL

⁵⁴⁵

HRAVPKDKWV

⁵⁵⁵

LNHEDLVLGE

⁵⁶⁵

QIGRGNFGEV

⁵⁷⁵

FSGRLRADNT

⁵⁸⁵

LVAVKSCRET

⁵⁹⁵

LPPDLKAKFL

⁶⁰⁵

QEARILKQYS

⁶¹⁵

HPNIVRLIGV

⁶²⁵

CTQKQPIYIV

⁶³⁵

MELVQGGDFL

⁶⁴⁵

TFLRTEGARL

⁶⁵⁵

RVKTLLQMVG

⁶⁶⁵

DAAAGMEYLE

⁶⁷⁵

SKCCIHRDLA

⁶⁸⁵

ARNCLVTEKN

⁶⁹⁵

VLKISDFGMS

⁷⁰⁵

REEADGVYAA

⁷¹⁵

SGGLRQVPVK

⁷²⁵

WTAPEALNYG

⁷³⁵

RYSSESDVWS

⁷⁴⁵

FGILLWETFS

⁷⁵⁵

LGASPYPNLS

⁷⁶⁵

NQQTREFVEK

⁷⁷⁵

GGRLPCPELC

⁷⁸⁵

PDAVFRLMEQ

⁷⁹⁵

CWAYEPGQRP

⁸⁰⁵

SFSTIYQELQ

⁸¹⁵

SIRKRH

Residue

Distance (Å)

HIS456

3.504

TRP554

3.950

LEU556

4.863

GLU559

3.398

ASP560

4.021

ILE567

3.517

GLY568

3.415

ARG569

3.388

GLY570

4.309

VAL575

3.924

LEU580

3.845

ARG581

3.675

ASP583

3.260

THR585

2.738

ALA588

3.212

LYS590

3.840

GLU607

3.481

SER615

4.767

Residue

Distance (Å)

VAL620

4.171

ARG621

2.942

LEU622

3.569

ILE623

3.223

MET636

3.753

GLU637

2.904

LEU638

3.403

VAL639

2.807

GLN640

4.963

GLY642

3.458

ASP643

3.743

ARG687

2.884

ASN688

3.840

LEU690

3.294

SER700

3.312

ASP701

3.497

PHE702

4.924

Click to View More Binding Site Information of This Target and Ligand Pair

Ligand Name: NVP-TAE684

Ligand Info

Structure Description

Crystal structure of human Feline Sarcoma Viral Oncogene Homologue (v-FES)in complex with TAE684

PDB:4E93

Method

X-ray diffraction

Resolution

1.84 Å

Mutation

[4]

PDB Sequence

SMIPEVQKPL

⁴⁵⁵

HEQLWYHGAI

⁴⁶⁵

PRAEVAELLV

⁴⁷⁵

HSGDFLVRES

⁴⁸⁵

QQEYVLSVLW

⁴⁹⁷

DGLPRHFIIQ

⁵⁰⁷

SLDNLYRLEG

⁵¹⁷

EGFPSIPLLI

⁵²⁷

DHLLSTQQPL

⁵³⁷

TKKSGVVLHR

⁵⁴⁷

AVPKDKWVLN

⁵⁵⁷

HEDLVLGEQI

⁵⁶⁷

GRGNFGEVFS

⁵⁷⁷

GRLRADNTLV

⁵⁸⁷

AVKSCRETLP

⁵⁹⁷

PDLKAKFLQE

⁶⁰⁷

ARILKQYSHP

⁶¹⁷

NIVRLIGVCT

⁶²⁷

QKQPIYIVME

⁶³⁷

LVQGGDFLTF

⁶⁴⁷

LRTEGARLRV

⁶⁵⁷

KTLLQMVGDA

⁶⁶⁷

AAGMEYLESK

⁶⁷⁷

CCIHRDLAAR

⁶⁸⁷

NCLVTEKNVL

⁶⁹⁷

KISDFGMSRE

⁷⁰⁷

VPVKWTAPEA

⁷³¹

LNYGRYSSES

⁷⁴¹

DVWSFGILLW

⁷⁵¹

ETFSLGASPY

⁷⁶¹

PNLSNQQTRE

⁷⁷¹

FVEKGGRLPC

⁷⁸¹

PELCPDAVFR

⁷⁹¹

LMEQCWAYEP

⁸⁰¹

GQRPSFSTIY

⁸¹¹

QELQSIRKRH

⁸²¹

Residue

Distance (Å)

ILE567

3.344

GLY568

4.267

ARG569

3.625

GLY570

3.483

ASN571

4.605

VAL575

3.654

ALA588

3.436

LYS590

2.803

VAL620

4.303

MET636

3.759

GLU637

3.328

Residue

Distance (Å)

LEU638

3.504

VAL639

2.978

GLN640

3.544

GLY642

3.588

ASP643

3.722

THR646

4.016

ARG687

3.546

ASN688

3.519

LEU690

3.524

SER700

3.175

ASP701

4.026

Click to View More Binding Site Information of This Target with Different Ligands

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues. The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021). Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function. Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006). Human Similarity Proteins Human Tissue Distribution Human Pathway Affiliation

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.

The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021).

Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.

Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006).

Human Similarity Proteins

Human Tissue Distribution

Human Pathway Affiliation

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Mixed lineage kinase 1 (MAP3K9)	PF00069 ; PF14604	34.155 (97/284)	1.63E-36
NIMA-related kinase 6 (NEK6)	PF00069	27.308 (71/260)	2.96E-24
SPS1/STE20-related protein kinase YSK4 (YSK4)	PF00069	27.626 (71/257)	2.84E-23
NIMA-related kinase 7 (NEK7)	PF00069	25.984 (66/254)	8.41E-23
Microtubule affinity regulating kinase 3 (MARK3)	PF02149 ; PF00069 ; PF00627 More >>	32.579 (72/221)	1.05E-22
Serine/threonine-protein kinase MARK1 (MARK1)	PF02149 ; PF00069 ; PF00627 More >>	33.333 (75/225)	1.09E-22
Protein kinase C theta (PRKCQ)	PF00130 ; PF00069 ; PF00433 More >>	27.273 (60/220)	2.31E-22
Serine/threonine-protein kinase MARK2 (MARK2)	PF02149 ; PF00069 ; PF00627 More >>	32.735 (73/223)	4.91E-22
Serine/threonine-protein kinase 24 (STK24)	PF00069	28.512 (69/242)	1.64E-21
MAP/microtubule affinity-regulating kinase 4 (MARK4)	PF02149 ; PF00069 ; PF00627 More >>	31.944 (69/216)	2.26E-21
Serine/threonine-protein kinase ULK2 (ULK2)	PF12063 ; PF00069	32.735 (73/223)	2.63E-21
Oxidative stress responsive 1 (OXSR1)	PF12202 ; PF00069	27.526 (79/287)	3.91E-21
Protein kinase C delta (PRKCD)	PF00130 ; PF00069 ; PF00433 More >>	28.846 (60/208)	3.94E-21
Serine/threonine-protein kinase 26 (STK26)	PF00069	28.049 (69/246)	1.06E-20
Serine/threonine-protein kinase 25 (STK25)	PF00069	28.395 (69/243)	1.11E-20
Ribosomal protein S6 kinase alpha-1 (RSK1)	PF00069 ; PF00433	28.163 (69/245)	1.27E-20
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	PF16579 ; PF00069	27.843 (71/255)	1.75E-20
Cyclin-dependent kinase 3 (CDK3)	PF00069	30.928 (60/194)	1.81E-20
MST-1 protein kinase (STK4)	PF11629 ; PF00069	26.693 (67/251)	3.51E-20
Unc-51 like kinase 3 (ULK3)	PF04212 ; PF00069	26.996 (71/263)	5.74E-20
Serine/threonine-protein kinase ULK1 (ULK1)	PF12063 ; PF00069	31.646 (75/237)	7.41E-20
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)	PF18397 ; PF12179 ; PF00069 More >>	30.233 (65/215)	1.06E-19
Serine/threonine-protein kinase 3 (STK3)	PF11629 ; PF00069	26.693 (67/251)	1.80E-19
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX)	PF00069	28.436 (60/211)	1.94E-19
Cyclin-dependent kinase 1 (CDK1)	PF00069	29.798 (59/198)	2.31E-19
Death-associated protein kinase 3 (DAPK3)	PF00069	30.455 (67/220)	2.36E-19
Ribosomal protein S6 kinase alpha-3 (RSK3)	PF00069 ; PF00433	26.939 (66/245)	2.57E-19
Cyclin-dependent kinase 6 (CDK6)	PF00069	31.188 (63/202)	2.94E-19
Cyclin-dependent kinase 4 (CDK4)	PF00069	29.902 (61/204)	2.99E-19
Testis-specific serine kinase 2 (TSSK2)	PF00069	28.571 (74/259)	3.30E-19
Death-associated protein kinase 2 (DAPK2)	PF00069	28.261 (65/230)	3.32E-19
Ribosomal protein S6 kinase alpha-2 (RSK2)	PF00069 ; PF00433	26.939 (66/245)	3.99E-19
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	PF16579 ; PF00069	26.953 (69/256)	4.80E-19
Putative serine/threonine-protein kinase PRKY (PRKY)	PF00069	28.643 (57/199)	5.34E-19
BR serine/threonine kinase 2 (BRSK2)	PF00069	31.336 (68/217)	6.12E-19
Serine/threonine-protein kinase Nek3 (NEK3)	PF00069	27.132 (70/258)	8.52E-19
Calcium/calmodulin-dependent protein kinase type 1B (PNCK)	PF00069	31.915 (60/188)	9.95E-19
Ste-20-related kinase (STK39)	PF12202 ; PF00069	26.132 (75/287)	1.51E-18
Aurora kinase A (AURKA)	PF00069	24.903 (64/257)	1.79E-18
TAO kinase 3 (TAOK3)	PF00069	27.692 (72/260)	2.35E-18
BR serine/threonine kinase 1 (BRSK1)	PF00069	29.880 (75/251)	3.48E-18
Protein kinase C beta (PRKCB)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	30.500 (61/200)	3.56E-18
Serine/threonine-protein kinase Nek4 (NEK4)	PF00069	28.295 (73/258)	4.05E-18
Aurora kinase C (AURKC)	PF00069	25.385 (66/260)	4.33E-18
MEK kinase kinase 2 (MAP4K2)	PF00780 ; PF00069	31.746 (60/189)	4.75E-18
Serine/threonine-protein kinase Nek5 (NEK5)	PF00069	25.101 (62/247)	5.00E-18
Salt-inducible kinase 2 (SIK2)	PF00069	27.778 (70/252)	5.15E-18
Cyclin-dependent kinase-like 2 (CDKL2)	PF00069	31.250 (65/208)	6.28E-18
Doublecortin-like kinase 3 (DCLK3)	PF00069	29.688 (57/192)	7.25E-18
Cyclin-dependent kinase 2 (CDK2)	PF00069	28.351 (55/194)	7.39E-18
TAO kinase 1 (TAOK1)	PF00069	26.136 (69/264)	8.37E-18
Mitogen-activated protein kinase kinase kinase 15 (MAP3K15)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	27.132 (70/258)	1.06E-17
Myosin-IIIa (MYO3A)	PF00612 ; PF00063 ; PF00069 More >>	26.441 (78/295)	1.07E-17
Calcium/calmodulin-dependent protein kinase type 1G (CAMK1G)	PF00069	27.854 (61/219)	1.10E-17
Ribosomal protein S6 kinase alpha-6 (RSK6)	PF00069 ; PF00433	26.122 (64/245)	1.17E-17
Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)	PF18397 ; PF12179 ; PF00069 More >>	28.095 (59/210)	1.57E-17
TRAF2 and NCK interacting kinase (TNIK)	PF00780 ; PF00069	27.969 (73/261)	1.60E-17
Testis-specific serine/threonine-protein kinase 1 (TSSK1B)	PF00069	28.958 (75/259)	1.72E-17
ERK activator kinase 1 (MEK1)	PF00069	29.327 (61/208)	2.74E-17
PKC-delta-interacting protein kinase (RIPK4)	PF12796 ; PF00069	26.415 (70/265)	2.75E-17
Cyclin-dependent kinase-like 3 (CDKL3)	PF00069	29.500 (59/200)	3.30E-17
Apoptosis signal-regulating kinase 2 (MAP3K6)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	29.386 (67/228)	3.93E-17
ERK activator kinase 5 (MAP2K5)	PF00564 ; PF00069	25.170 (74/294)	4.02E-17
Apoptosis signal-regulating kinase 1 (MAP3K5)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	27.888 (70/251)	5.86E-17
Cyclin-dependent kinase 5 (CDK5)	PF00069	28.111 (61/217)	6.39E-17
ERK activator kinase 2 (MEK2)	PF00069	29.808 (62/208)	6.87E-17
Testis-specific serine/threonine-protein kinase 4 (TSSK4)	PF00069	26.563 (68/256)	1.02E-16
Serine/threonine-protein kinase TAO2 (TAOK2)	PF00069	29.787 (56/188)	1.14E-16
Cyclin-dependent kinase-like 4 (CDKL4)	PF00069	29.412 (60/204)	1.55E-16
MEK kinase kinase 3 (MAP4K3)	PF00780 ; PF00069	29.949 (59/197)	1.62E-16
Cyclin-dependent kinase 15 (CDK15)	PF00069	27.586 (56/203)	1.91E-16
Serine/threonine-protein kinase Nek10 (NEK10)	PF00069	24.042 (69/287)	1.92E-16
Cyclin-dependent kinase 7 (CDK7)	PF00069	29.167 (56/192)	2.05E-16
Misshapen-like kinase 1 (MINK1)	PF00780 ; PF00069	30.332 (64/211)	2.56E-16
SNF-related serine/threonine-protein kinase (SNRK)	PF00069	27.237 (70/257)	2.76E-16
Cyclin-dependent kinase-like 1 (CDKL1)	PF00069	28.922 (59/204)	3.38E-16
Serine/threonine-protein kinase 33 (STK33)	PF00069	28.511 (67/235)	5.91E-16
Ribosomal protein S6 kinase beta-2 (RPS6KB2)	PF00069 ; PF00433	26.378 (67/254)	6.44E-16
NIMA-related kinase 2 (NEK2)	PF00069	25.283 (67/265)	6.87E-16
Cyclin-dependent kinase 14 (CDK14)	PF00069	25.728 (53/206)	8.49E-16
Calcium/calmodulin-dependent protein kinase type 1D (CAMK1D)	PF00069	31.606 (61/193)	9.10E-16
NUAK family SNF1-like kinase 2 (NUAK2)	PF00069	28.821 (66/229)	1.04E-15
MEK kinase kinase 1 (MAP4K1)	PF00780 ; PF00069	30.612 (60/196)	1.12E-15
SIK family kinase 3 (SIK3)	PF00069	28.959 (64/221)	1.16E-15
STE20-related serine/threonine-protein kinase (SLK)	PF00069 ; PF12474	30.732 (63/205)	1.19E-15
Cyclin-dependent kinase 16 (CDK16)	PF12330 ; PF00069	24.107 (54/224)	1.22E-15
Cyclin-dependent kinase 17 (CDK17)	PF12330 ; PF00069	26.425 (51/193)	1.28E-15
RAC-beta serine/threonine-protein kinase (AKT2)	PF00169 ; PF00069 ; PF00433 More >>	26.522 (61/230)	1.34E-15
Cyclin-dependent kinase 12 (CDK12)	PF00069	27.239 (73/268)	1.77E-15
Death-associated protein kinase 1 (DAPK1)	PF00023 ; PF12796 ; PF13637 ; PF00531 ; PF00069 More >>	27.778 (65/234)	1.78E-15
RAC-gamma serine/threonine-protein kinase (AKT3)	PF00169 ; PF00069 ; PF00433 More >>	27.962 (59/211)	1.81E-15
Omphalocele kinase 1 (NUAK1)	PF00069	26.887 (57/212)	1.83E-15
Protein kinase G2 (PRKG2)	PF00027 ; PF00069	26.577 (59/222)	1.91E-15
Serine/threonine-protein kinase Nek11 (NEK11)	PF00069	25.794 (65/252)	2.05E-15
Doublecortin-like kinase 1 (DCLK1)	PF03607 ; PF00069	29.534 (57/193)	2.21E-15
Hormonally up-regulated neu tumor-associated kinase (HUNK)	PF00069	26.961 (55/204)	2.28E-15
Cyclin-dependent kinase 9 (CDK9)	PF00069	28.846 (60/208)	2.46E-15
Protein kinase C alpha (PRKCA)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	27.500 (55/200)	2.61E-15
Protein kinase C eta type (PRKCH)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	30.049 (61/203)	2.69E-15
Fused homolog (STK36)	PF13646 ; PF00069	25.758 (51/198)	2.75E-15
cAMP-dependent protein kinase catalytic subunit beta (PRKACB)	PF00069	28.070 (64/228)	4.04E-15
MEK kinase kinase 4 (MAP4K4)	PF00780 ; PF00069	29.858 (63/211)	4.45E-15
Calmodulin-dependent kinase II (CAMKK2)	PF00069	28.870 (69/239)	4.47E-15
Myosin light chain kinase 2 (MYLK2)	PF00069	26.728 (58/217)	4.91E-15
Cyclin-dependent kinase 18 (CDK18)	PF00069	26.364 (58/220)	5.29E-15
Serine/threonine-protein kinase PAK 6 (PAK6)	PF00786 ; PF00069	27.372 (75/274)	6.20E-15
Salt-inducible kinase 1 (SIK1)	PF00069	26.923 (70/260)	7.24E-15
Putative serine/threonine-protein kinase SIK1B (SIK1B)	PF00069	26.923 (70/260)	7.30E-15
Serine/threonine-protein kinase H1 (PSKH1)	PF00069	29.245 (62/212)	8.71E-15
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)	PF00069	27.586 (72/261)	8.99E-15
Serine/threonine-protein kinase ICK (CILK1)	PF00069	25.907 (50/193)	9.36E-15
Protein kinase N2 (PKN2)	PF02185 ; PF00069 ; PF00433 More >>	27.982 (61/218)	1.09E-14
Extracellular signal-regulated kinase 2 (ERK2)	PF00069	30.457 (60/197)	1.12E-14
Serine/threonine-protein kinase 10 (STK10)	PF00069 ; PF12474	29.442 (58/197)	1.14E-14
Serine/threonine-protein kinase PAK 5 (PAK5)	PF00786 ; PF00069	28.571 (58/203)	1.19E-14
Testis-specific serine/threonine-protein kinase 6 (TSSK6)	PF00069	29.119 (76/261)	1.20E-14
Cyclin-dependent kinase 13 (CDK13)	PF12330 ; PF00069	25.514 (62/243)	1.37E-14
Myosin-IIIb (MYO3B)	PF00612 ; PF00063 ; PF00069 More >>	28.223 (81/287)	1.44E-14
Aurora kinase B (AURKB)	PF00069	26.459 (68/257)	1.47E-14
MAPK/ERK kinase kinase 1 (MAP3K1)	PF00069	28.426 (56/197)	1.52E-14
Microtubule-associated serine/threonine-protein kinase 2 (MAST2)	PF08926 ; PF17820 ; PF00069 More >>	28.085 (66/235)	1.64E-14
Doublecortin-like kinase 2 (DCLK2)	PF03607 ; PF00069	27.523 (60/218)	1.73E-14
PAK-4 protein kinase (PAK4)	PF00786 ; PF00069	28.641 (59/206)	1.93E-14
Serine/threonine-protein kinase Nek8 (NEK8)	PF00069 ; PF00415	26.437 (69/261)	2.01E-14
MAP kinase p38 (MAPK12)	PF00069	30.808 (61/198)	2.36E-14
Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5)	PF00780 ; PF00069	27.411 (54/197)	2.40E-14
Polo-like kinase 4 (PLK4)	PF00069 ; PF18190 ; PF18409 More >>	25.962 (54/208)	2.45E-14
Calcium/calmodulin-dependent protein kinase type 1 (CAMK1)	PF00069	28.241 (61/216)	2.72E-14
G protein-coupled receptor kinase 5 (GRK5)	PF00069 ; PF00615	27.103 (58/214)	3.10E-14
Myosin light kinase (MYLK)	PF16620 ; PF00041 ; PF07679 ; PF00069 More >>	27.315 (59/216)	3.42E-14
NIMA-related kinase 1 (NEK1)	PF00069	23.954 (63/263)	3.90E-14
Cyclin-dependent kinase 10 (CDK10)	PF00069	30.457 (60/197)	4.19E-14
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6)	PF00069	26.766 (72/269)	5.66E-14
PAK-2 protein kinase (PAK2)	PF00786 ; PF00069	28.141 (56/199)	5.94E-14
Serine/threonine-protein kinase STK11 (STK11)	PF00069	27.138 (73/269)	5.94E-14
Extracellular signal-regulated kinase 5 (ERK5)	PF00069	30.952 (65/210)	6.40E-14
Stress-activated protein kinase 2a (p38 alpha)	PF00069	28.780 (59/205)	6.59E-14
Serine/threonine-protein kinase D3 (PRKD3)	PF00130 ; PF00169 ; PF00069 More >>	27.861 (56/201)	6.67E-14
Ribosomal protein S6 kinase beta-1 (S6K1)	PF00069 ; PF00433	25.463 (55/216)	6.67E-14
Serine/threonine-protein kinase D2 (PRKD2)	PF00130 ; PF00069	27.363 (55/201)	7.53E-14
Leucine-rich repeat kinase 2 (LRRK2)	PF16095 ; PF12799 ; PF13855 ; PF00069 ; PF08477 More >>	26.415 (70/265)	7.63E-14
Rho-associated protein kinase 2 (ROCK2)	PF00069 ; PF08912	27.160 (66/243)	9.50E-14
Serine/threonine-protein kinase ULK4 (ULK4)	PF00069	26.222 (59/225)	9.58E-14
Cyclin-dependent kinase 11B (CDK11B)	PF00069	29.442 (58/197)	1.20E-13
Serine/threonine-protein kinase H2 (PSKH2)	PF00069	28.704 (62/216)	1.24E-13
Protein kinase N1 (PKN1)	PF02185 ; PF00069 ; PF00433 More >>	27.854 (61/219)	1.41E-13
cAMP-dependent protein kinase catalytic subunit gamma (PRKACG)	PF00069	25.882 (66/255)	1.42E-13
Phosphoinositide dependent protein kinase-1 (PDPK1)	PF14593 ; PF00069	23.902 (49/205)	1.44E-13
cAMP-dependent protein kinase catalytic subunit alpha (PRKACA)	PF00069	27.273 (60/220)	1.44E-13
Serine/threonine-protein kinase NIM1 (NIM1K)	PF00069	27.228 (55/202)	1.59E-13
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)	PF00069	27.381 (69/252)	1.73E-13
Protein kinase D (PRKD1)	PF00130 ; PF00169 ; PF00069 More >>	26.368 (53/201)	1.95E-13
Putative 3-phosphoinositide-dependent protein kinase 2 (PDPK2P)	PF00069	23.902 (49/205)	1.98E-13
Receptor-interacting serine/threonine-protein kinase 3 (RIPK3)	PF00069 ; PF12721	28.148 (76/270)	2.36E-13
Cyclin-dependent kinase 11A (CDK11A)	PF00069	29.798 (59/198)	2.48E-13
Myosin light chain kinase 3 (MYLK3)	PF00069	27.397 (60/219)	2.53E-13
Stress-activated protein kinase 2b (p38 beta)	PF00069	30.472 (71/233)	2.54E-13
Serine/threonine-protein kinase 32C (STK32C)	PF00069	26.122 (64/245)	2.56E-13
Myosin light chain kinase family member 4 (MYLK4)	PF00069	26.522 (61/230)	2.74E-13
Serine/threonine-protein kinase Sgk1 (SGK1)	PF00069 ; PF00433	25.854 (53/205)	2.89E-13
ERK activator kinase 7 (MAP2K7)	PF00069	29.858 (63/211)	2.98E-13
PAK-1 protein kinase (PAK1)	PF00786 ; PF00069	26.482 (67/253)	3.32E-13
Extracellular signal-regulated kinase 1 (ERK1)	PF00069	29.146 (58/199)	3.41E-13
G protein-coupled receptor kinase 6 (GRK6)	PF00069 ; PF00615	27.358 (58/212)	3.63E-13
Serine/threonine-protein kinase MAK (MAK)	PF00069	24.870 (48/193)	3.85E-13
CDC42 binding protein kinase alpha (DMPK-like alpha)	PF00130 ; PF00780 ; PF08826 ; PF15796 ; PF00069 ; PF00433 More >>	26.838 (73/272)	4.56E-13
IL-1 receptor-associated kinase 1 (IRAK1)	PF00531 ; PF00069	28.365 (59/208)	5.22E-13
MAPK/ERK kinase kinase 4 (MAP3K4)	PF19431 ; PF00069	25.200 (63/250)	5.54E-13
Serine/threonine-protein kinase PAK 3 (PAK3)	PF00786 ; PF00069	26.482 (67/253)	5.55E-13
Protein kinase C iota (PRKCI)	PF00130 ; PF00564 ; PF00069 ; PF00433 More >>	28.302 (60/212)	5.94E-13
Rho-associated protein kinase 1 (ROCK1)	PF00069 ; PF08912	28.440 (62/218)	6.51E-13
Maternal embryonic leucine zipper kinase (MELK)	PF02149 ; PF00069	26.772 (68/254)	7.43E-13
Serine/threonine-protein kinase MRCK beta (CDC42BPB)	PF00130 ; PF00780 ; PF08826 ; PF15796 ; PF00069 More >>	25.311 (61/241)	7.44E-13
RAC-alpha serine/threonine-protein kinase (AKT1)	PF00169 ; PF00069 ; PF00433 More >>	26.407 (61/231)	7.69E-13
Ribosomal protein S6 kinase alpha-5 (RSK5)	PF00069 ; PF00433	27.076 (75/277)	8.14E-13
Serine/threonine-protein kinase Sgk2 (SGK2)	PF00069 ; PF00433	26.570 (55/207)	9.54E-13
Nik-related protein kinase (NRK)	PF00780 ; PF00069	26.667 (64/240)	9.93E-13
Protein kinase C zeta (PRKCZ)	PF00130 ; PF00564 ; PF00069 ; PF00433 More >>	25.581 (55/215)	1.01E-12
Mitogen-activated protein kinase 13 (MAPK13)	PF00069	28.384 (65/229)	1.46E-12
Serine/threonine-protein kinase 17B (STK17B)	PF00069	25.328 (58/229)	1.52E-12
Proto-oncogene serine/threonine-protein kinase mos (MOS)	PF00069	26.000 (78/300)	1.71E-12
G protein-coupled receptor kinase 4 (GRK4)	PF00069 ; PF00615	26.768 (53/198)	1.88E-12
Protein kinase C epsilon (PRKCE)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	28.141 (56/199)	1.94E-12
Microtubule-associated serine/threonine-protein kinase 1 (MAST1)	PF08926 ; PF17820 ; PF00069 More >>	28.037 (60/214)	1.99E-12
Cyclin-dependent kinase-like 5 (CDKL5)	PF00069	25.728 (53/206)	3.50E-12
Protein kinase C gamma (PRKCG)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	26.047 (56/215)	3.91E-12
Mitogen-activated protein kinase 6 (MAPK6)	PF00069	30.189 (64/212)	5.53E-12
Microtubule-associated serine/threonine-protein kinase 3 (MAST3)	PF08926 ; PF17820 ; PF02163 ; PF00069 More >>	26.168 (56/214)	6.26E-12
Serine/threonine-protein kinase Sgk3 (SGK3)	PF00069 ; PF00433 ; PF00787 More >>	25.366 (52/205)	7.45E-12
Serine/threonine-protein kinase SBK1 (SBK1)	PF00069	26.778 (64/239)	7.68E-12
Serine/threonine-protein kinase pim-2 (PIM2)	PF00069	25.191 (66/262)	7.73E-12
Serine/threonine-protein kinase pim-1 (PIM1)	PF00069	26.154 (68/260)	9.03E-12
Protein kinase N3 (PKN3)	PF02185 ; PF00069 ; PF00433 More >>	27.189 (59/217)	9.34E-12
Cytoplasmic DRAK1 (STK17A)	PF00069	25.974 (60/231)	1.08E-11
CaM-kinase IV kinase (CAMKK1)	PF00069	29.825 (51/171)	1.21E-11
Calcium/calmodulin-dependent protein kinase type II subunit gamma (CAMK2G)	PF08332 ; PF00069	25.769 (67/260)	1.49E-11
Leucine-rich repeat serine/threonine-protein kinase 1 (LRRK1)	PF12796 ; PF16095 ; PF00069 ; PF08477 More >>	29.870 (69/231)	1.60E-11
Microtubule-associated serine/threonine-protein kinase 4 (MAST4)	PF08926 ; PF17820 ; PF02163 ; PF00069 More >>	27.103 (58/214)	1.81E-11
Checkpoint kinase-1 (CHK1)	PF00069	27.273 (72/264)	1.94E-11
MAPK/ERK kinase kinase 3 (MAP3K3)	PF00564 ; PF00069	27.586 (56/203)	2.61E-11
Tyrosine-protein kinase EIF2AK2 (p68)	PF00035 ; PF00069	22.300 (64/287)	2.81E-11
Calcium/calmodulin-dependent protein kinase type IV (CAMK4)	PF00069	29.231 (57/195)	2.83E-11
Serine/threonine-protein kinase Chk2 (RAD53)	PF00498 ; PF00069	29.258 (67/229)	2.95E-11
Protein kinase G1 (PRKG1)	PF00027 ; PF16808 ; PF00069 More >>	25.000 (56/224)	2.99E-11
Serine/threonine-protein kinase 32A (STK32A)	PF00069	23.348 (53/227)	3.02E-11
Serine/threonine-protein kinase PDIK1L (PDIK1L)	PF00069	23.904 (60/251)	3.18E-11
Yet another novel kinase 2 (STK32B)	PF00069	26.291 (56/213)	3.86E-11
Polo-like kinase 2 (PLK2)	PF00069 ; PF00659	23.810 (60/252)	4.66E-11
Serine/threonine-protein kinase WNK1 (WNK1)	PF12202 ; PF00069	28.986 (60/207)	6.48E-11
Citron Rho-interacting kinase (CIT)	PF00780 ; PF00169 ; PF00069 More >>	26.027 (57/219)	7.26E-11
Serine/threonine-protein kinase Nek9 (NEK9)	PF00069 ; PF00415	24.479 (47/192)	7.67E-11
NF-kappa-B-activating kinase (TBK1)	PF00069 ; PF18394 ; PF18396 More >>	24.885 (54/217)	8.09E-11
Serine/threonine-protein kinase NLK (NLK)	PF00069	31.500 (63/200)	8.45E-11
Serine/threonine-protein kinase MRCK gamma (CDC42BPG)	PF00130 ; PF00780 ; PF08826 ; PF00069 More >>	26.636 (57/214)	1.07E-10
Stress-activated protein kinase JNK3 (JNK3)	PF00069	27.863 (73/262)	1.19E-10
Polo-like kinase 1 (PLK1)	PF00069 ; PF00659	25.000 (63/252)	1.20E-10
MAPK/MAK/MRK overlapping kinase (MOK)	PF00069	26.020 (51/196)	1.39E-10
Stress-activated protein kinase JNK2 (JNK2)	PF00069	30.808 (61/198)	1.39E-10
Calcium/calmodulin-dependent protein kinase type II subunit alpha (CAMK2A)	PF08332 ; PF00069	26.050 (62/238)	1.40E-10
Ribosomal protein S6 kinase-related protein (RSKR)	PF00069	29.560 (47/159)	1.61E-10
Serine/threonine-protein kinase greatwall (MASTL)	PF00069	27.673 (44/159)	1.73E-10
Membrane-associated kinase (PKMYT1)	PF00069	27.368 (52/190)	1.87E-10
Mitogen-activated protein kinase 15 (MAPK15)	PF00069	26.577 (59/222)	1.95E-10
MAPK-activated protein kinase 2 (MAPKAPK2)	PF00069	24.670 (56/227)	2.45E-10
Stress-activated protein kinase JNK1 (JNK1)	PF00069	29.437 (68/231)	3.05E-10
CaM kinase-like vesicle-associated protein (CAMKV)	PF00069	25.714 (54/210)	3.21E-10
MAPK-activated protein kinase 3 (MAPKAPK3)	PF00069	25.683 (47/183)	3.46E-10
Cyclin-dependent kinase 20 (CDK20)	PF00069	26.695 (63/236)	3.48E-10
Serine/threonine-protein kinase PLK3 (PLK3)	PF00069 ; PF00659	23.982 (53/221)	3.74E-10
NDR2 protein kinase (STK38L)	PF00069 ; PF00433	23.529 (56/238)	4.19E-10
Beta-adrenergic receptor kinase 1 (ADRBK1)	PF00169 ; PF00069 ; PF00615 More >>	26.761 (57/213)	4.39E-10
Testis-specific serine/threonine-protein kinase 3 (TSSK3)	PF00069	26.613 (66/248)	4.76E-10
MAPK/ERK kinase kinase 2 (MAP3K2)	PF00564 ; PF00069	26.108 (53/203)	5.31E-10
Endoplasmic reticulum to nucleus signaling 1 (ERN1)	PF00069 ; PF06479	29.615 (77/260)	6.63E-10
WNK lysine-deficient protein kinase 3 (WNK3)	PF12202 ; PF00069	28.571 (60/210)	6.70E-10
Calcium/calmodulin-dependent protein kinase type II subunit delta (CAMK2D)	PF08332 ; PF00069	26.047 (56/215)	7.82E-10
Phosphorylase kinase testis gamma 2 (PHKG2)	PF00069	27.488 (58/211)	8.07E-10
Beta-adrenergic receptor kinase 2 (ADRBK2)	PF00169 ; PF00069 ; PF00615 More >>	27.723 (56/202)	8.49E-10
Obscurin (OBSCN)	PF00041 ; PF07679 ; PF00612 ; PF00069 ; PF00621 More >>	25.592 (54/211)	1.11E-09
Activin receptor type IB (ACVR1B)	PF01064 ; PF00069 ; PF08515 More >>	27.064 (59/218)	1.57E-09
Glycogen synthase kinase-3 alpha (GSK-3A)	PF00069	31.754 (67/211)	1.58E-09
Serine/threonine-protein kinase WNK4 (WNK4)	PF12202 ; PF00069	28.634 (65/227)	1.62E-09
STE20-related kinase adapter protein beta (STRADB)	PF00069	27.626 (71/257)	1.65E-09
TGF-beta receptor type I (TGFBR1)	PF01064 ; PF00069 ; PF08515 More >>	25.346 (55/217)	1.99E-09
Triple functional domain protein (TRIO)	PF00650 ; PF07679 ; PF00169 ; PF00069 ; PF00621 ; PF16609 ; PF00018 ; PF00435 More >>	26.038 (69/265)	2.13E-09
NDR1 protein kinase (STK38)	PF00069 ; PF00433	22.581 (63/279)	2.14E-09
IL-1 receptor-associated kinase 3 (IRAK3)	PF00531 ; PF00069	22.353 (76/340)	2.38E-09
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform (PHKG1)	PF00069	27.326 (47/172)	2.79E-09
TBC domain-containing protein kinase-like protein (TBCK)	PF00069 ; PF00566 ; PF00581 More >>	23.305 (55/236)	3.03E-09
Cyclin-dependent kinase 19 (CDK19)	PF00069	25.472 (54/212)	4.08E-09
Serine/threonine-protein kinase NIK (MAP3K14)	PF00069	27.500 (55/200)	4.21E-09
Rhodopsin kinase GRK1 (GRK1)	PF00069 ; PF00615	26.289 (51/194)	4.75E-09
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE)	PF00069 ; PF18394 ; PF18396 More >>	26.316 (55/209)	5.29E-09
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B)	PF08332 ; PF00069	26.540 (56/211)	5.36E-09
Serine/threonine-protein kinase 35 (STK35)	PF00069	23.770 (58/244)	6.33E-09
Serine/threonine-protein kinase cot (COT)	PF00069	25.381 (50/197)	6.58E-09
Serine/threonine-protein kinase LATS1 (LATS1)	PF00069 ; PF00627	24.900 (62/249)	7.98E-09
Casein kinase I delta (CSNK1D)	PF00069	25.088 (71/283)	9.02E-09
PIM-3 protein kinase (PIM3)	PF00069	27.413 (71/259)	1.02E-08
TGF-beta-stimulated factor 1 (STK16)	PF00069	20.629 (59/286)	1.26E-08
Serine/threonine-protein kinase tousled-like 2 (TLK2)	PF00069	24.427 (64/262)	1.31E-08
Myotonin-protein kinase (DMPK)	PF08826 ; PF00069	24.554 (55/224)	1.38E-08
Titin (TTN)		24.434 (54/221)	1.63E-08
Rhodopsin kinase GRK7 (GRK7)	PF00069 ; PF00615	25.352 (54/213)	1.94E-08
Bone morphogenetic protein receptor (BMPR2)	PF01064 ; PF00069	26.141 (63/241)	2.02E-08
Serine/threonine-protein kinase WNK2 (WNK2)	PF12202 ; PF00069	27.803 (62/223)	2.70E-08
Casein kinase I epsilon (CSNK1E)	PF00069	24.555 (69/281)	4.25E-08
Peripheral plasma membrane protein CASK (CASK)	PF00625 ; PF02828 ; PF00595 ; PF00069 ; PF00018 More >>	26.818 (59/220)	8.33E-08
Striated muscle preferentially expressed protein kinase (SPEG)	PF07679 ; PF00069 ; PF16650 More >>	24.797 (61/246)	8.51E-08
Ribosomal protein S6 kinase alpha-4 (RPS6KA4)	PF00069 ; PF00433	25.664 (58/226)	8.59E-08
Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4)	PF12745 ; PF00069 ; PF05773 ; PF13393 More >>	28.169 (40/142)	1.01E-07
Serine/threonine-protein kinase tousled-like 1 (TLK1)	PF00069	26.425 (51/193)	1.53E-07
Cyclin-dependent kinase 8 (CDK8)	PF00069	23.423 (52/222)	1.69E-07
Mitogen-activated protein kinase 4 (MAPK4)	PF00069	30.409 (52/171)	2.15E-07
Glycogen synthase kinase-3 beta (GSK-3B)	PF00069	30.275 (66/218)	2.19E-07
PAS domain-containing serine/threonine-protein kinase (PASK)	PF13426 ; PF00069	26.316 (55/209)	3.54E-07
PDZ binding kinase (PBK)	PF00069	24.793 (60/242)	4.39E-07
Homeodomain interacting protein kinase 2 (HIPK2)	PF00069	24.444 (55/225)	5.63E-07
Serine/threonine-protein kinase SBK2 (SBK2)	PF00069	25.263 (48/190)	1.32E-06
Serine/threonine-protein kinase/endoribonuclease IRE2 (ERN2)	PF00069 ; PF06479	26.540 (56/211)	1.67E-06
Casein kinase I gamma-1 (CSNK1G1)	PF12605 ; PF00069	29.448 (48/163)	2.26E-06
Casein kinase I gamma-3 (CSNK1G3)	PF12605 ; PF00069	29.630 (48/162)	2.92E-06
Homeodomain-interacting protein kinase 4 (HIPK4)	PF00069	25.328 (58/229)	3.23E-06
PRKR-like endoplasmic reticulum kinase (PERK)	PF00069	34.021 (33/97)	4.49E-06
BMP-2-inducible protein kinase (BMP2K)	PF15282 ; PF00069	24.312 (53/218)	6.20E-06
Large tumor suppressor homolog 2 (LATS2)	PF00069 ; PF00433	25.517 (37/145)	6.44E-06
Homeodomain-interacting protein kinase 1 (HIPK1)	PF00069	24.444 (55/225)	7.41E-06
Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)	PF00069	24.444 (55/225)	7.52E-06
Casein kinase I gamma-2 (CSNK1G2)	PF12605 ; PF00069	29.630 (48/162)	8.07E-06
Anti-mullerian hormone II receptor (AMHR2)	PF00069	23.620 (77/326)	9.69E-06
Homeodomain-interacting protein kinase 3 (HIPK3)	PF00069	24.878 (51/205)	9.73E-06
Serine/threonine kinase-like domain-containing protein STKLD1 (STKLD1)	PF00069	28.571 (28/98)	1.25E-05
Kalirin (KALRN)	PF13716 ; PF00041 ; PF07679 ; PF00169 ; PF00069 ; PF00621 ; PF16609 ; PF00435 More >>	24.038 (50/208)	1.41E-05
MAP kinase signal-integrating kinase 2 (MKNK2)	PF00069	25.543 (47/184)	2.76E-05
Wee1-like protein kinase (WEE1)	PF00069	24.823 (70/282)	5.46E-05
Adaptor-associated kinase 1 (AAK1)	PF00069	23.767 (53/223)	1.04E-04
Dual specificity protein kinase TTK (MPS1)	PF00069	22.685 (49/216)	1.05E-04
STE20-related kinase adapter protein alpha (STRADA)	PF00069	24.153 (57/236)	1.72E-04
Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)	PF00069	23.256 (50/215)	2.04E-04
Casein kinase II alpha prime (CSNK2A2)	PF00069	25.121 (52/207)	2.32E-04
Activin receptor type IIA (ACVR2A)	PF01064 ; PF00069	24.402 (51/209)	2.62E-04
MAPK-activated protein kinase 5 (MAPKAPK5)	PF00069	22.905 (41/179)	2.65E-04
Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4)	PF00069	24.171 (51/211)	4.12E-04
Serine/threonine-protein kinase Kist (UHMK1)	PF00069 ; PF00076	26.364 (58/220)	6.75E-04
Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1)	PF00069	27.083 (26/96)	7.68E-04
Casein kinase II alpha (CSNK2A1)	PF00069	24.390 (50/205)	1.00E-03
Wee1-like protein kinase 2 (WEE2)	PF00069	19.930 (57/286)	1.00E-03
Cyclin-G-associated kinase (GAK)	PF00069 ; PF10409	21.965 (38/173)	2.00E-03
Serine/threonine-protein kinase PRP4 homolog (PRPF4B)	PF00069	28.814 (34/118)	2.00E-03
Casein kinase I isoform alpha-like (CSNK1A1L)	PF00069	25.974 (40/154)	4.00E-03
Tribbles homolog 2 (TRIB2)	PF00069	22.843 (45/197)	5.00E-03
Interleukin-1 receptor-associated kinase-like 2 (IRAK2)	PF00531 ; PF00069	23.129 (34/147)	5.00E-03
Click to Show/Hide the Information of Human Similarity Proteins


Note: If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.

KEGG Pathway	Pathway ID	Affiliated Target	Pathway Map
Axon guidance	hsa04360	Affiliated Target
Class: Organismal Systems => Development and regeneration	Pathway Hierarchy

Chemical Structure based Activity Landscape of Target

Top

Target Regulators

Top

Target-interacting Proteins

Target-interacting Proteins Info

References

Top

REF 1

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.

REF 2

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.

REF 3

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell. 2008 Sep 5;134(5):793-803.

REF 4

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase. Chem Biol. 2012 Apr 20;19(4):529-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN